title: Topical photodynamic therapy with 5-aminolevulinic acid for cervical high-risk HPV infection.
abstract: OBJECTIVE
  To investigate the clinical efficacy of 5-aminolevulinic acid photodynamic therapy (ALA-PDT) for cervical high-risk HPV (HR-HPV) infection.
  
  
  METHODS
  In this prospective study, a total of 76 patients with persistent cervical HR-HPV infection were randomly divided into two groups. The treatment group (39 patients) received three treatments of ALA-PDT at two-week intervals. The control group (37 patients) received no treatment. All patients were followed up for 9 months. Hybrid Capture HPV DNA Assay and ThinPrep cytology test (TCT) were performed for both groups. Patients with abnormal TCT results received colposcopic biopsy before treatment and during follow-ups.
  
  
  RESULTS
  HR-HPV remission rates were 64.10% (25/39) in the treatment group and 24.32% (9/37) in the control group at 3 month follow-up. Complete remission rates were 76.92% (30/39) and 32.40% (12/37), respectively, in the two groups at 9 month follow-up. There was a statistically significant difference between the two groups (P<0.01). Conversion rates of abnormal TCT results were 81.81% (9/11) in the treatment group and 12.50% (1/8) in the control group at 3 months, and 90.90% (10/11) and 25.00% (2/8), respectively, at 9 months. Five of six patients with CIN I in the treatment group and no patients in the control group achieved complete response at 9 months. There was a statistically significant difference between the two groups (P<0.01).
  
  
  CONCLUSIONS
  Topical ALA-PDT is an effective, safe and well tolerated treatment for cervical HR-HPV infection.
authors.affiliation: Department of Dermatology, Beijing Hospital, China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Fu
authors.affiliation: Department of Dermatology, Beijing Hospital, China.
authors.forename: Yingqiu
authors.initials: Y
authors.lastname: Bao
authors.affiliation: Department of Obstetrics and Gynecology, Beijing Hospital, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Hui
authors.affiliation: Department of Dermatology, Beijing Hospital, China.
authors.forename: Xiaoman
authors.initials: X
authors.lastname: Gao
authors.affiliation: Department of Dermatology, Beijing Hospital, China.
authors.forename: Min
authors.initials: M
authors.lastname: Yang
authors.affiliation: Department of Dermatology, Beijing Hospital, China. Electronic address: changjianmin@medmail.com.cn.
authors.forename: Jianmin
authors.initials: J
authors.lastname: Chang
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000622:Aminolevulinic Acid / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008875:Middle Aged; D030361:Papillomavirus Infections / Q000188:drug therapy* / Q000473:pathology*; D010778:Photochemotherapy / Q000379:methods*; D017319:Photosensitizing Agents / Q000008:administration & dosage; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000473:pathology* / Q000517:prevention & control*; D055815:Young Adult
chemical_list: D017319:Photosensitizing Agents; D000622:Aminolevulinic Acid
keywords: 5-aminolevulinic acid; High-risk human papillomavirus (HR-HPV)